Rezolute (Rezolute) Growth Rank : 0 (As of Jun. 06, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Rezolute Growth Rank?

Rezolute has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Rezolute Growth Rank Related Terms

Thank you for viewing the detailed overview of Rezolute's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rezolute (Rezolute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.rezolutebio.com

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Executives

Brian Kenneth Roberts	officer: Chief Medical Officer	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie	director	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis	director	60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher	director	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc.	10 percent owner	132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet	director	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim	director	C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc.	10 percent owner	700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller	officer: VP Finance & CAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim	director	49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung	director	101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola	officer: Chief Financial Officer	111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp	10 percent owner	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch	director	C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields	officer: Chief Accounting Officer	890 SANTA CRUZ AVE., MENLO PARK CA 94025